

93205

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

05-05-03

Requester's Full Name: David Lukton Examiner #: 71263 Date: _____
 Art Unit: 1653 Phone Number 30 803213 Serial Number: 09-836636
 Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL
Mail Box: 9B01 Exr Rm: 9B05
 If more than one search is submitted, please prioritize searches in order of need.

 Title: Macrocyclic NS-3 serine protease inhibitors of Hepatitis C virus comprising alkyl and aryl alanine P2 moieties

Applicants: Venkatraman, Srikanth; Chen, Kevin X.; Arasappan, ashok; njoroge, f. George; girijavallabhan, viyyoor m.; ganguly, ashit k.; chan, tin-yau; mc kittrick, brian a.; yao, nanhua hugh; prongay, andrew j.; madison, vincent s.;

Earliest Priority Date: 4/19/00

X = -CH₂- or -NH or -O-


R1 = anything;

R2 = anything;

R3 = anything;

n = 0 - 5

p = 2 - 6



Mary Jane Ruhl
 Tech. Info. Specialist, STIC
 TC-1600
 CM-1, Room 6A-06
 Phone: 605-1155

RECEIVED

MAY -5 2003

STIC/CHM DIVISION

STAFF USE ONLY

Searcher: _____
 Searcher Phone #: _____
 Searcher Location: _____
 Date Searcher Picked Up: 5/5/03
 Date Completed: 5/7/03
 Searcher Prep & Review Time: _____
 Clerical Prep Time: _____
 Online Time: _____

Type of Search

NA Sequence (#) _____
 AA Sequence (#) _____
 Structure (#) _____
 Bibliographic _____
 Litigation _____
 Fulltext _____
 Patent Family _____
 Other _____

Vendors and cost where applicable

STN _____
 Dialog _____
 Questel/Orbit _____
 Dr.Link _____
 Lexis/Nexis _____
 Sequence Systems _____
 WWW/Internet _____
 Other (specify) _____

=> d ibib abs hitstr l4 1-1

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:798207 HCAPLUS

DOCUMENT NUMBER: 135:344735

TITLE: Preparation of macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine p2 moieties

INVENTOR(S): Venkatraman, Srikanth; Chen, Kevin X.; Arasappan, Ashok; Njoroge, F. George; Girijavallabhan, Viyyoor M.; Chan, Tin-Yau; McKittrick, Brian A.; Prongay, Andrew J.; Madison, Vincent S.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 218 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2001081325 | A2 | 20011101 | WO 2001-US12530 | 20010417 |
| WO 2001081325 | A3 | 20020801 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2002016294 | A1 | 20020207 | US 2001-836636 | 20010417 |
| BR 2001010104 | A | 20030107 | BR 2001-10104 | 20010417 |
| EP 1274724 | A2 | 20030115 | EP 2001-927142 | 20010417 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| NO 2002005030 | A | 20021218 | NO 2002-5030 | 20021018 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | US 2000-198204P | P 20000419 |
| | | | WO 2001-US12530 | W 20010417 |
| OTHER SOURCE(S): MARPAT 135:344735 | | | | |
| GI | | | | |



AB Macrocyclic compds. I [E, X, Y may be independently present or absent, and if present may be (un)substituted (cyclo)alkyl, aryl, heteroalkyl, heteroaryl, ether, amino, sulfide, sulfone, amide, sulfonamide, urea, carbamate, hydrazide, carbonyl, etc.; R1 = acyl or boryl groups; Z = O, N, or CH; W = null, CO, CS, SO2, C:NR (R = H, alkyl, cycloalkyl, aryl, etc.); Q = (NR)_p (p = 0-6), O, S, CH2, CHR, CRR' (R' = any group given for R) or a double bond toward V; A = O, CH2, (CHR)_p, (CHRCHR')_p, (CRR')_p, NR, S, SO2, CO or a bond; G = (CH2)_p, (CHR)_p, (CRR')_p, NR, O, S, SO2, SO2NH, CO or a bond towards E or V; R2, R3, R4 = H, (un)substituted (hetero)alkyl, -aryl or -cycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, etc.], including enantiomers and pharmaceutically acceptable salts, were prepd. as hepatitis C virus (HCV) protease inhibitors. Thus, peptide II was prepd. by a multistep procedure involving cyclization of intermediate cyclopentadiene-*eta*.6-ruthenium-4-chlorophenylpropionic acid-cyclohexylglycine-*m*-tyrosine-OMe. II showed $K_i = 0.001-1.0 \mu\text{M}$ in the HCV protease assay. The invention also discloses pharmaceutical compns. comprising I as well as methods of using them to treat disorders assocd. with the HCV protease.


IT 371111-26-1P 371111-27-2P 371111-37-4P
371111-38-5P 371111-39-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of macrocyclic NS3-serine protease inhibitors of hepatitis C virus)

RN 371111-26-1 HCAPLUS

CN Glycinamide, (2S)-N-(4-carboxy-1-oxobutyl)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (1.fwdarw.2)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-27-2 HCAPLUS

CN Glycinamide, (2S)-N-(7-carboxy-1-oxoheptyl)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (1.fwdarw.2)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-37-4 HCAPLUS

CN Glycinamide, (2S)-N-(3-carboxy-1-oxopropyl)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (1.fwdarw.2)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-38-5 HCAPLUS

CN Glycinamide, (2S)-N-(5-carboxy-1-oxopentyl)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (1.fwdarw.2)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-39-6 HCAPLUS

CN Glycinamide, (2S)-N-(6-carboxy-1-oxohexyl)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (1.fwdarw.2)-lactam, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 12:34:03 ON 07 MAY 2003)

FILE 'REGISTRY' ENTERED AT 12:34:17 ON 07 MAY 2003

L1

STR

L2

0 S L1

L3

5 S L1 FULL

5 comps from Registry - see of one stat for structure (attached)

FILE 'HCAPLUS' ENTERED AT 12:48:06 ON 07 MAY 2003

L4

1 S L3

1 cit from CA Plus


FILE 'CAOLD' ENTERED AT 12:51:01 ON 07 MAY 2003

L5

0 S L4

0 cit from CA Old

=> d que stat 14
L1 STR



REP G1=(2-6) CH2
REP G2=(0-5) CH2
VAR G3=CH2/NH/O
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE
L3 5 SEA FILE=REGISTRY SSS FUL L1
L4 1 SEA FILE=HCAPLUS ABB=ON L3

Lukton 09/836,636

07/05/2003

=> d ibib abs hitstr 125 1-1

L25 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:798207 HCAPLUS

DOCUMENT NUMBER: 135:344735

TITLE: Preparation of macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine p2 moieties

INVENTOR(S): Venkatraman, Srikanth; Chen, Kevin X.; Arasappan, Ashok; Njoroge, F. George; Girijavallabhan, Viyyoor M.; Chan, Tin-Yau; McKittrick, Brian A.; Prongay, Andrew J.; Madison, Vincent S.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 218 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-------------------|----------|
| WO 2001081325 | A2 | 20011101 | WO 2001-US12530 | 20010417 |
| WO 2001081325 | A3 | 20020801 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| US 2002016294 | A1 | 20020207 | US 2001-836636 | 20010417 |
| BR 2001010104 | A | 20030107 | BR 2001-10104 | 20010417 |
| EP 1274724 | A2 | 20030115 | EP 2001-927142 | 20010417 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| NO 2002005030 | A | 20021218 | NO 2002-5030 | 20021018 |
| PRIORITY APPLN. INFO.: | | | US 2000-198204P P | 20000419 |
| | | | WO 2001-US12530 W | 20010417 |

OTHER SOURCE(S): MARPAT 135:344735

GI



AB Macrocyclic compds. I [E, X, Y may be independently present or absent, and if present may be (un)substituted (cyclo)alkyl, aryl, heteroalkyl, heteroaryl, ether, amino, sulfide, sulfone, amide, sulfonamide, urea, carbamate, hydrazide, carbonyl, etc.; R1 = acyl or boryl groups; Z = O, N, or CH; W = null, CO, CS, SO₂, C:NR (R = H, alkyl, cycloalkyl, aryl, etc.); Q = (NR)_p (p = 0-6), O, S, CH₂, CHR, CRR' (R' = any group given for R) or a double bond toward V; A = O, CH₂, (CHR)_p, (CHRCHR')_p, (CRR')_p, NR, S, SO₂, CO or a bond; G = (CH₂)_p, (CHR)_p, (CRR')_p, NR, O, S, SO₂, SO₂NH, CO or a bond towards E or V; R₂, R₃, R₄ = H, (un)substituted (hetero)alkyl, -aryl or -cycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, etc.], including enantiomers and pharmaceutically acceptable salts, were prepd. as **hepatitis C virus (HCV) protease inhibitors**. Thus, peptide II was prepd. by a multistep procedure involving cyclization of intermediate cyclopentadiene- ϵ -6-ruthenium-4-chlorophenylpropionic acid-cyclohexylglycine-m-tyrosine-OMe. II showed $K_i = 0.001-1.0 \mu\text{M}$ in the HCV protease assay. The invention also discloses pharmaceutical compns. comprising I as well as methods of using them to treat disorders assocd. with the HCV protease.

IT 371110-87-1P 371110-89-3P 371110-91-7P
 371110-93-9P 371110-95-1P 371110-97-3P
 371110-99-5P 371111-01-2P 371111-03-4P
 371111-08-9P 371111-09-0P 371111-11-4P
 371111-13-6P 371111-15-8P 371111-17-0P
 371111-19-2P 371111-23-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(prepn. of macrocyclic NS3-**serine** protease inhibitors of

hepatitis C virus)

RN 371110-87-1 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371110-89-3 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371110-91-7 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[4-(4-hydroxyphenyl)-1-oxobutyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371110-93-9 HCAPLUS
 CN Glycine, (2S)-2-cyclohexyl-N-[5-(4-hydroxyphenyl)-1-oxopentyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OBu-t


RN 371110-95-1 HCAPLUS
CN Glycine, N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371110-97-3 HCAPLUS
CN Glycine, (2S)-2-cyclohexyl-N-(7-hydroxy-1-oxoheptyl)glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371110-99-5 HCAPLUS

RN 3/11110-99-5 HCAPLEUS
CN Glycine, (2S)-2-cyclohexyl-N-(6-hydroxy-1-oxohexyl)glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— OBU-t

RN 371111-01-2 HCAPLUS

RN 3/1111-01-2 HCAPLUS
 CN Glycine, (2S)-2-cyclohexylglycyl-3-(7-carboxy-1-heptenyl)-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 5-(1,1-dimethylethyl) ester, (2.fwdarw.1)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 371111-03-4 HCAPLUS

CN Glycine, (2S)-2-cyclohexylglycyl-3-(7-carboxyheptyl)-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 5-(1,1-dimethylethyl) ester, (2.fwdarw.1)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-08-9 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[[(6-hydroxyhexyl)oxy]carbonyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-09-0 HCAPLUS

CN Glycine, (2S)-2-cyclohexylglycyl-1-(7-carboxyheptyl)-L-histidyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 5-(1,1-dimethylethyl) ester, (2.fwdarw.1)-lactam, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371111-11-4 HCAPLUS


CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-(2S)-2-cyclohexylglycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, phenylmethyl ester, cyclic (1.fwdarw.3)-ether, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 371111-13-6 HCAPLUS

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-(2S)-2-cyclohexylglycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoyl-, phenylmethyl ester, cyclic (1.fwdarw.3)-ether (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371111-15-8 HCAPLUS

CN Glycine, N-acetyl-L-tyrosyl-(2S)-2-cyclohexylglycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl

ester, cyclic (1.fwdarw.3)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-17-0 HCAPLUS

CN Glycine, N-acetyl-L-tyrosyl-(2S)-2-cyclohexylglycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.3)-ether (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-19-2 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-(.alpha.S)-.alpha.,3-dihydroxybenzenepropanoyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-23-8 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-3-hydroxy-D-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 371110-88-2P 371110-90-6P 371110-92-8P
 371110-94-0P 371110-96-2P 371110-98-4P
 371111-00-1P 371111-02-3P 371111-04-5P
 371111-05-6P 371111-06-7P 371111-07-8P
 371111-10-3P 371111-12-5P 371111-14-7P
 371111-16-9P 371111-18-1P 371111-20-5P
 371111-21-6P 371111-22-7P 371111-24-9P
 371111-25-0P 371111-26-1P 371111-27-2P
 371111-28-3P 371111-29-4P 371111-30-7P
 371111-31-8P 371111-32-9P 371111-33-0P
 371111-34-1P 371111-35-2P 371111-36-3P
 371111-37-4P 371111-38-5P 371111-39-6P
 371111-40-9P 371112-25-3P 371112-26-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of macrocyclic NS3-serine protease inhibitors of hepatitis C virus)

RN 371110-88-2 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371110-90-6 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoyl-, cyclic (1.fwdarw.2)-ether (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371110-92-8 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[4-(4-hydroxyphenyl)-1-oxobutyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371110-94-0 HCAPLUS
 CN Glycine, (2S)-2-cyclohexyl-N-[5-(4-hydroxyphenyl)-1-oxopentyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

-CO₂H

RN 371110-96-2 HCAPLUS

CN Glycine, N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, cyclic
(1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371110-98-4 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-(7-hydroxy-1-oxoheptyl)glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, cyclic
(1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371111-00-1 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-(6-hydroxy-1-oxohexyl)glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

CO₂H

RN 371111-02-3 HCAPLUS

CN Glycine, (2S)-2-cyclohexylglycyl-3-(7-carboxy-1-heptenyl)-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2.fwdarw.1)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 371111-04-5 HCAPLUS

CN Glycine, (2S)-2-cyclohexylglycyl-3-(7-carboxyheptyl)-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-05-6 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[[[5-hydroxypentyl)amino]carbonyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-06-7 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[[(5-hydroxypentyl)amino]carbonyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-07-8 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[[(6-hydroxyhexyl)oxy]carbonyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-10-3 HCAPLUS

CN Glycine, (2S)-2-cyclohexylglycyl-1-(7-carboxyheptyl)-L-histidyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-12-5 HCAPLUS

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-(2S)-2-cyclohexylglycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, cyclic (1.fwdarw.3)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-14-7 HCAPLUS

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-(2S)-2-cyclohexylglycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoyl-, cyclic (1.fwdarw.3)-ether (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-16-9 HCAPLUS

CN Glycine, N-acetyl-L-tyrosyl-(2S)-2-cyclohexylglycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, cyclic (1.fwdarw.3)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-18-1 HCAPLUS

CN Glycine, N-acetyl-L-tyrosyl-(2S)-2-cyclohexylglycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoyl-, cyclic (1.fwdarw.3)-ether (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-20-5 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-(.alpha.S)-.alpha.,3-dihydroxybenzenepropanoyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-21-6 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-22-7 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-(7-hydroxy-1-oxoheptyl)glycyl-3-hydroxyphenylalanyl-3-amino-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-24-9 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-3-hydroxy-D-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-25-0 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[[[(6-hydroxyhexyl)oxy]carbonyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-26-1 HCAPLUS

CN Glycinamide, (2S)-N-(4-carboxy-1-oxobutyl)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (1.fwdarw.2)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-27-2 HCAPLUS

CN Glycinamide, (2S)-N-(7-carboxy-1-oxoheptyl)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (1.fwdarw.2)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-28-3 HCAPLUS

CN Glycinamide, (2S)-N-(8-carboxy-1-oxooctyl)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (1S,2S)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-29-4 HCAPLUS

CN Glycinamide, (2S)-N-[[3-(carboxymethyl)phenyl]acetyl]-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (1S,2S)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-30-7 HCAPLUS

CN Glycinamide, (2S)-N-[[4-(carboxymethyl)phenyl]acetyl]-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (1.fwdarw.2)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-31-8 HCAPLUS

CN Glycinamide, N-(3-carboxy-1-oxopropyl)-D-.alpha.-aspartyl-(2S)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (12.fwdarw.3)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-32-9 HCAPLUS

CN Glycinamide, N-(4-carboxy-1-oxobutyl)-D-.alpha.-aspartyl-(2S)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (12.fwdarw.3)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-33-0 HCAPLUS

CN Glycinamide, N-(3-carboxy-1-oxopropyl)-D-.alpha.-glutamyl-(2S)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (12.fwdarw.3)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-34-1 HCAPLUS

CN Glycinamide, N-(4-carboxy-1-oxobutyl)-D-.alpha.-glutamyl-(2S)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (12.fwdarw.3)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-35-2 HCAPLUS

CN Glycinamide, N-(3-carboxy-1-oxopropyl)glycyl-(2S)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (1.fwdarw.3)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-36-3 HCAPLUS

CN Glycinamide, N-(4-carboxy-1-oxobutyl)glycyl-(2S)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (1.fwdarw.3)-lactam, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-37-4 HCAPLUS

CN Glycinamide, (2S)-N-(3-carboxy-1-oxopropyl)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (1.fwdarw.2)-lactam, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-38-5 HCAPLUS

CN Glycinamide, (2S)-N-(5-carboxy-1-oxopentyl)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (1.fwdarw.2)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-39-6 HCAPLUS

CN Glycinamide, (2S)-N-(6-carboxy-1-oxohexyl)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (1.fwdarw.2)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-40-9 HCAPLUS

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-glutamyl-(2S)-2-cyclohexylglycyl-L-lysyl-3-amino-2-oxohexanoyl-, 5-propyl ester, (1.fwdarw.3)-lactam (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371112-25-3 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[[[(6-hydroxyhexyl)oxy]carbonyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoyl]glycyl-N-methyl-2-phenyl-, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371112-26-4 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-(7-hydroxy-1-oxoheptyl)glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 149885-80-3

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(prepn. of macrocyclic NS3-serine protease inhibitors of hepatitis C virus)

RN 149885-80-3 HCAPLUS

CN Proteinase, polyprotein-processing, NS3 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 298-12-4, Glyoxylic acid 627-00-9, 4-Chlorobutyric acid
627-05-4, 1-Nitrobutane 821-41-0, 5-Hexen-1-ol
867-13-0, Triethyl phosphonoacetate 1119-60-4,
6-Heptenoic acid 1745-17-1 2019-34-3 3601-66-9
6282-88-8, Benzenepropanol, 4-chloro- 7389-87-9

30515-28-7, 7-Bromoheptanoic acid 34087-14-4


68090-88-0 80049-61-2 123053-23-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of macrocyclic NS3-serine protease inhibitors of
hepatitis C virus)


RN 298-12-4 HCAPLUS

CN Acetic acid, oxo- (9CI) (CA INDEX NAME)




RN 627-00-9 HCAPLUS

CN Butanoic acid, 4-chloro- (9CI) (CA INDEX NAME)




RN 627-05-4 HCAPLUS

CN Butane, 1-nitro- (6CI, 8CI, 9CI) (CA INDEX NAME)




RN 821-41-0 HCAPLUS

CN 5-Hexen-1-ol (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 867-13-0 HCAPLUS

CN Acetic acid, (diethoxyphosphinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 1119-60-4 HCAPLUS

CN 6-Heptenoic acid (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 1745-17-1 HCAPLUS

CN 6-Heptenoic acid, methyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 2019-34-3 HCAPLUS

CN Benzenepropanoic acid, 4-chloro- (9CI) (CA INDEX NAME)




RN 3601-66-9 HCAPLUS

CN Benzeneacetic acid, .alpha.-[[(1,1-dimethylethoxy)carbonyl]amino]- (9CI)
(CA INDEX NAME)

RN 6282-88-8 HCAPLUS


CN Benzenepropanol, 4-chloro- (9CI) (CA INDEX NAME)



RN 7389-87-9 HCAPLUS

CN L-Histidine, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 30515-28-7 HCAPLUS

CN Heptanoic acid, 7-bromo- (6CI, 8CI, 9CI) (CA INDEX NAME)




RN 34087-14-4 HCAPLUS
 CN L-Alanine, 3-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 68090-88-0 HCAPLUS
 CN L-Phenylalanine, 4-chloro-N-[(1,1-dimethylethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 80049-61-2 HCAPLUS
 CN Ruthenium(1+), tris(acetonitrile)(.eta.5-2,4-cyclopentadien-1-yl)-, hexafluorophosphate(1-) (9CI) (CA INDEX NAME)

CM 1


CRN 80049-60-1
 CMF C11 H14 N3 Ru
 CCI GCS



CM 2

CRN 16919-18-9
 CMF F6 P


CCI CCS



RN 123053-23-6 HCAPLUS

CN L-Phenylalanine, 4-chloro-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

IT 3710-42-7P 14565-11-8P 55478-55-2P
 75677-02-0P 161725-12-8P 166196-05-0P
 166196-06-1P 172035-28-8P 228404-10-2P
 236393-88-7P 367258-42-2P 367258-43-3P
 367258-44-4P 367258-45-5P 367258-46-6P
 367258-47-7P 367258-48-8P 367258-49-9P
 367259-26-5P 367259-52-7P 367260-51-3P
 368454-24-4P 368454-26-6P 371111-41-0P
 371111-42-1P 371111-43-2P 371111-44-3P
 371111-45-4P 371111-46-5P 371111-47-6P
 371111-48-7P 371111-49-8P 371111-50-1P
 371111-51-2P 371111-52-3P 371111-53-4P
 371111-54-5P 371111-55-6P 371111-56-7P
 371111-57-8P 371111-58-9P 371111-59-0P
 371111-60-3P 371111-61-4P 371111-62-5P
 371111-63-6P 371111-64-7P 371111-65-8P
 371111-66-9P 371111-67-0P 371111-68-1P
 371111-69-2P 371111-70-5P 371111-71-6P
 371111-72-7P 371111-73-8P 371111-74-9P
 371111-75-0P 371111-76-1P 371111-77-2P
 371111-78-3P 371111-79-4P 371111-80-7P
 371111-81-8P 371111-82-9P 371111-83-0P
 371111-84-1P 371111-85-2P 371111-86-3P
 371111-87-4P 371111-88-5P 371111-89-6P
 371111-90-9P 371111-91-0P 371111-92-1P
 371111-93-2P 371111-94-3P 371111-95-4P
 371111-96-5P 371111-97-6P 371111-98-7P
 371111-99-8P 371112-00-4P 371112-01-5P
 371112-02-6P 371112-03-7P 371112-04-8P
 371112-05-9P 371112-07-1P 371112-08-2P

371112-09-3P 371112-10-6P 371112-11-7P
 371112-12-8P 371112-13-9P 371112-14-0P
 371112-15-1P 371112-16-2P 371112-17-3P
 371112-18-4P 371112-19-5P 371112-20-8P
 371112-21-9P 371112-22-0P 371112-23-1P
 371112-24-2P 371241-12-2P 371241-14-4P
 371241-18-8P 371241-24-6P 371241-28-0P
 371241-36-0P 371241-43-9P 371241-46-2P
 371241-50-8P 371241-54-2P 371755-64-5P
 371755-65-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(prepn. of macrocyclic NS3-serine protease inhibitors of
 hepatitis C virus)


RN 3710-42-7 HCAPLUS

CN Heptanoic acid, 7-hydroxy- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 14565-11-8 HCAPLUS


CN Heptanoic acid, 7-hydroxy-, methyl ester (8CI, 9CI) (CA INDEX NAME)



RN 55478-55-2 HCAPLUS


CN L-Phenylalanine, N-acetyl-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 75677-02-0 HCAPLUS

CN Benzenepropanal, 4-chloro- (9CI) (CA INDEX NAME)




RN 161725-12-8 HCAPLUS


CN Benzenepentanoic acid, 4-chloro- (9CI) (CA INDEX NAME)



RN 166196-05-0 HCAPLUS
 CN Hexanoic acid, 3-amino-2-hydroxy- (9CI) (CA INDEX NAME)



RN 166196-06-1 HCAPLUS
 CN Hexanoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy- (9CI)
 (CA INDEX NAME)




RN 172035-28-8 HCAPLUS
 CN Ruthenium, [(1,2,3,4,5,6-.eta.)-4-chloro-N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalaninato](.eta.5-2,4-cyclopentadien-1-yl)-, hexafluorophosphate(1-)
) (9CI) (CA INDEX NAME)

CM 1


CRN 172035-27-7
 CMF C19 H22 Cl N O4 Ru
 CCI CCS

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 16940-81-1


CMF F6 P . H

CCI CCS



● H⁺.

RN 228404-10-2 HCAPLUS
CN Carbonochloridic acid, 5-hexenyl ester (9CI) (CA INDEX NAME)




RN 236393-88-7 HCAPLUS
CN Ruthenium, [(1,2,3,4,5,6-.eta.)-N-acetyl-4-chloro-L-phenylalaninato] (.eta.5-2,4-cyclopentadien-1-yl)-, hexafluorophosphate(1-)
(9CI) (CA INDEX NAME)


CM 1

CRN 236393-87-6
CMF C16 H16 Cl N O3 Ru
CCI CCS

PAGE 1-A



PAGE 2-A




CM 2


CRN 16940-81-1

CMF F6 P . H


CCI CCS

● H⁺


RN 367258-42-2 HCAPLUS
 CN Hexanoic acid, 2-hydroxy-3-nitro- (9CI) (CA INDEX NAME)



RN 367258-43-3 HCAPLUS
 CN Glycine, N-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-1-oxohexyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 367258-44-4 HCAPLUS
 CN Glycine, N-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-1-oxohexyl]-, (9CI) (CA INDEX NAME)



RN 367258-45-5 HCAPLUS
 CN Carbamic acid, [(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 367258-46-6 HCAPLUS

CN Glycinamide, N-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-1-oxohexyl]glycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 367258-47-7 HCAPLUS

CN Glycinamide, N-(3-amino-2-hydroxy-1-oxohexyl)glycyl-N,N-dimethyl-2-phenyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 367258-48-8 HCAPLUS

CN Glycinamide, N-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-1-oxohexyl]glycyl-N-methyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 367258-49-9 HCAPLUS

CN Glycinamide, N-(3-amino-2-hydroxy-1-oxohexyl)glycyl-N-methyl-2-phenyl-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 367259-26-5 HCAPLUS

CN Benzeneacetamide, .alpha.-amino-N,N-dimethyl-, monohydrochloride, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 367259-52-7 HCAPLUS

CN Glycine, N-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-1-oxohexyl]glycyl-2-phenyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 367260-51-3 HCAPLUS

CN Glycine, N-(3-amino-2-hydroxy-1-oxohexyl)glycyl-2-phenyl-, 1,1-dimethylethyl ester, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 368454-24-4 HCAPLUS
 CN Ruthenium, [(1,2,3,4,5,6-eta.)-4-chlorobenzenepropanoato](.eta.5-2,4-cyclopentadien-1-yl)-, compd. with hydrogen hexafluorophosphate(1-) (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 368454-23-3
 CMF C14 H13 Cl O2 Ru
 CCI CCS

PAGE 1-A



PAGE 2-A




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS

● H⁺

RN 368454-26-6 HCAPLUS

CN Ruthenium, [(1,2,3,4,5,6-.eta.)-4-chlorobenzenepentanoato] (.eta.5-2,4-cyclopentadien-1-yl)-, compd. with hydrogen hexafluorophosphate(1-) (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 368454-25-5


CMF C16 H17 Cl O2 Ru

CCI CCS

PAGE 1-A



PAGE 2-A




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS




● H⁺

RN 371111-41-0 HCAPLUS

CN L-Phenylalanine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-42-1 HCAPLUS

CN L-Phenylalanine, (2S)-2-cyclohexylglycyl-3-hydroxy-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 371111-43-2 HCAPLUS

CN 2-Oxa-10,13-diazatricyclo[15.2.2.13,7]docosa-3,5,7(22),17,19,20-hexaene-9-carboxylic acid, 12-cyclohexyl-11,14-dioxo-, methyl ester, (9S,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-44-3 HCAPLUS

CN 2-Oxa-10,13-diazatricyclo[15.2.2.13,7]docosa-3,5,7(22),17,19,20-hexaene-9-carboxylic acid, 12-cyclohexyl-11,14-dioxo-, (9S,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-45-4 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-hydroxyhexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-46-5 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-hydroxyhexanoyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-47-6 HCAPLUS

CN 2-Oxa-10,13-diazatricyclo[16.2.2.13,7]tricoso-3,5,7(23),18,20,21-hexaene-9-carboxylic acid, 12-cyclohexyl-11,14-dioxo-, methyl ester, (9S,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-48-7 HCAPLUS


CN Glycine, (2S)-2-cyclohexyl-N-[4-(4-hydroxyphenyl)-1-oxobutyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-hydroxyhexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371111-49-8 HCAPLUS


CN Glycine, N-(3-amino-2-hydroxy-1-oxohexyl)-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 371111-50-1 HCAPLUS

CN 2-Pentenoic acid, 5-(4-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 371111-51-2 HCAPLUS


CN Benzenepentanoic acid, 4-chloro-, ethyl ester (9CI) (CA INDEX NAME)



RN 371111-52-3 HCAPLUS

CN 2-Oxa-10,13-diazatricyclo[17.2.2.13,7]tetracos-3,5,7(24),19,21,22-hexaene-9-carboxylic acid, 12-cyclohexyl-11,14-dioxo-, methyl ester, (9S,12S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371111-53-4 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[5-(4-hydroxyphenyl)-1-oxopentyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-hydroxyhexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

-OBu-t

RN 371111-54-5 HCAPLUS

CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]glycyl-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-55-6 HCAPLUS

CN L-Phenylalanine, glycyl-3-hydroxy-, methyl ester, monohydrochloride (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 371111-56-7 HCAPLUS
CN 2-Oxa-10,13-diazatricyclo[15.2.2.13,7]docosa-3,5,7(22),17,19,20-hexaene-9-carboxylic acid, 11,14-dioxo-, methyl ester, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371111-57-8 HCAPLUS
CN Glycine, N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-hydroxyhexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-58-9 HCAPLUS

CN L-Phenylalanine, (2S)-2-cyclohexyl-N-(1-oxo-6-heptenyl)glycyl-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-59-0 HCAPLUS

CN L-Phenylalanine, (2S)-2-cyclohexyl-N-(7-hydroxy-1-oxoheptyl)glycyl-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-60-3 HCAPLUS

CN 2-Oxa-10,13-diazabicyclo[14.3.1]eicosa-1(20),16,18-triene-14-carboxylic acid, 11-cyclohexyl-9,12-dioxo-, methyl ester, (11S,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-61-4 HCAPLUS

CN 2-Oxa-10,13-diazabicyclo[14.3.1]eicosa-1(20),16,18-triene-14-carboxylic acid, 11-cyclohexyl-9,12-dioxo-, (11S,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-62-5 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-(7-hydroxy-1-oxoheptyl)glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-hydroxyhexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-63-6 HCAPLUS

CN L-Phenylalanine, (2S)-2-cyclohexyl-N-(6-hydroxy-1-oxohexyl)glycyl-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-64-7 HCAPLUS

CN 2-Oxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxylic acid, 10-cyclohexyl-8,11-dioxo-, methyl ester, (10S,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-65-8 HCAPLUS

CN 2-Oxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxylic acid, 10-cyclohexyl-8,11-dioxo-, (10S,13S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-66-9 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-(6-hydroxy-1-oxohexyl)glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-hydroxyhexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—OBu-t

RN 371111-67-0 HCAPLUS

CN L-Phenylalanine, 3-iodo-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 371111-68-1 HCAPLUS

CN L-Phenylalanine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-3-iodo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-69-2 HCAPLUS

CN L-Phenylalanine, (2S)-2-cyclohexyl-N-(1-oxo-6-heptenyl)glycyl-3-iodo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371111-70-5 HCAPLUS


CN 4,7-Diazabicyclo[14.3.1]eicosa-1(20),14,16,18-tetraene-3-carboxylic acid, 6-cyclohexyl-5,8-dioxo-, methyl ester, (3S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 371111-71-6 HCAPLUS

CN 4,7-Diazabicyclo[14.3.1]eicosa-1(20),14,16,18-tetraene-3-carboxylic acid,
6-cyclohexyl-5,8-dioxo-, (3S,6S)- (9CI) (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry unknown.


RN 371111-72-7 HCAPLUS

CN Glycine, (2S)-2-cyclohexylglycyl-3-(7-carboxy-1-heptenyl)-L-phenylalanyl-3-
amino-2-hydroxyhexanoylglycyl-2-phenyl-, 5-(1,1-dimethylethyl) ester,
(2.fwdarw.1)-lactam, (2S)- (9CI) (CA INDEX NAME)Absolute stereochemistry.
Double bond geometry unknown.

RN 371111-73-8 HCAPLUS

CN 4,7-Diazabicyclo[14.3.1]eicosa-1(20),16,18-triene-3-carboxylic acid,
6-cyclohexyl-5,8-dioxo-, methyl ester, (3S,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-74-9 HCAPLUS

CN Glycine, (2S)-2-cyclohexylglycyl-3-(7-carboxyheptyl)-L-phenylalanyl-3-amino-2-hydroxyhexanoylglycyl-2-phenyl-, 5-(1,1-dimethylethyl) ester, (2.fwdarw.1)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-75-0 HCAPLUS


CN L-Phenylalanine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-3-[[5-[[[(1,1-dimethylethoxy)carbonyl]amino]pentyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371111-76-1 HCAPLUS
 CN L-Phenylalanine, (2S)-2-cyclohexylglycyl-3-[(5-aminopentyl)oxy]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 371111-77-2 HCAPLUS
 CN 2-Oxa-8,10,13-triazabicyclo[14.3.1]eicosa-1(20),16,18-triene-14-carboxylic acid, 11-cyclohexyl-9,12-dioxo-, methyl ester, (11S,14S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371111-78-3 HCAPLUS
 CN 2-Oxa-8,10,13-triazabicyclo[14.3.1]eicosa-1(20),16,18-triene-14-carboxylic acid, 11-cyclohexyl-9,12-dioxo-, (11S,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-79-4 HCAPLUS

CN L-Phenylalanine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-3-[[[(2-propenyloxy)carbonyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-80-7 HCAPLUS

CN L-Phenylalanine, (2S)-2-cyclohexylglycyl-3-[[[(2-propenyloxy)carbonyl]oxy]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 371111-81-8 HCAPLUS

CN L-Phenylalanine, (2S)-2-cyclohexyl-N-[(5-hexenyloxy)carbonyl]glycyl-3-[[[(2-propenyloxy)carbonyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-82-9 HCAPLUS

CN L-Phenylalanine, (2S)-2-cyclohexyl-N-[(5-hexenyloxy)carbonyl]glycyl-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-83-0 HCAPLUS

CN L-Phenylalanine, (2S)-2-cyclohexyl-N-[[[(6-hydroxyhexyl)oxy]carbonyl]glycyl-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-84-1 HCAPLUS

CN 2,9-Dioxabicyclo[15.3.1]heneicosa-1(21),17,19-triene-15-carboxylic acid, 12-cyclohexyl-10,13-dioxo-, methyl ester, (12S,15S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-85-2 HCAPLUS

CN 2,9-Dioxabicyclo[15.3.1]heneicosa-1(21),17,19-triene-15-carboxylic acid, 12-cyclohexyl-10,13-dioxo-, (12S,15S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-86-3 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[[[(6-hydroxyhexyl)oxy]carbonyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-hydroxyhexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-87-4 HCAPLUS

CN L-Histidine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-88-5 HCAPLUS

CN L-Histidine, (2S)-N-(8-bromo-1-oxooctyl)-2-cyclohexylglycyl-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 371111-89-6 HCAPLUS

CN 1,10,13,17-Tetraazabicyclo[14.2.1]nonadeca-16(19),17-diene-14-carboxylic acid, 11-cyclohexyl-9,12-dioxo-, methyl ester, (11S,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-90-9 HCAPLUS

CN 1,10,13,17-Tetraazabicyclo[14.2.1]nonadeca-16(19),17-diene-14-carboxylic acid, 11-cyclohexyl-9,12-dioxo-, (11S,14S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-91-0 HCAPLUS

CN 2-Oxa-10,13-diazatricyclo[15.2.2.13,7]docosa-3,5,7(22),17,19,20-hexaene-9-carboxylic acid, 12-cyclohexyl-15-[[[(1,1-dimethylethoxy)carbonyl]amino]-11,14-dioxo-, methyl ester, (9S,12S,15S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-92-1 HCAPLUS

CN 2-Oxa-10,13-diazatricyclo[15.2.2.13,7]docosa-3,5,7(22),17,19,20-hexaene-9-carboxylic acid, 12-cyclohexyl-15-[[[(1,1-dimethylethoxy)carbonyl]amino]-11,14-dioxo-, (9S,12S,15S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-93-2 HCAPLUS
 CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-(2S)-2-cyclohexylglycyl-3-hydroxy-L-phenylalanyl-3-amino-2-hydroxyhexanoylglycyl-2-phenyl-, phenylmethyl ester, cyclic (1.fwdarw.3)-ether, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

Ph

RN 371111-94-3 HCAPLUS
 CN Glycine, N-(3-amino-2-hydroxy-1-oxohexyl)-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 371111-95-4 HCAPLUS
 CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-(2S)-2-cyclohexylglycyl-3-hydroxy-L-phenylalanyl-3-amino-2-hydroxyhexanoyl-,

phenylmethyl ester, cyclic (1.fwdarw.3)-ether (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-96-5 HCAPLUS

CN 2-Oxa-10,13-diazatricyclo[15.2.2.13,7]docosa-3,5,7(22),17,19,20-hexaene-9-carboxylic acid, 15-(acetylamino)-12-cyclohexyl-11,14-dioxo-, methyl ester, (9S,12S,15S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-97-6 HCAPLUS

CN 2-Oxa-10,13-diazatricyclo[15.2.2.13,7]docosa-3,5,7(22),17,19,20-hexaene-9-carboxylic acid, 15-(acetylamino)-12-cyclohexyl-11,14-dioxo-, (9S,12S,15S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-98-7 HCAPLUS

CN Glycine, N-acetyl-L-tyrosyl-(2S)-2-cyclohexylglycyl-3-hydroxy-L-phenylalanyl-3-amino-2-hydroxyhexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.3)-ether (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371111-99-8 HCAPLUS


CN Glycine, N-acetyl-L-tyrosyl-(2S)-2-cyclohexylglycyl-3-hydroxy-L-phenylalanyl-3-amino-2-hydroxyhexanoyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.3)-ether (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371112-00-4 HCAPLUS
 CN Benzenepropanoic acid, .alpha.,3-dihydroxy-, phenylmethyl ester,
 (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371112-01-5 HCAPLUS
 CN Benzenepropanoic acid, .alpha.-hydroxy-3-[[(2-propenyloxy) carbonyl]oxy]-,
 phenylmethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371112-02-6 HCAPLUS
 CN Benzenepropanoic acid, .alpha.-[[(2S)-cyclohexyl[[(1,1-
 dimethylethoxy) carbonyl]amino]acetyl]oxy]-3-[[(2-propenyloxy) carbonyl]oxy]-
 , phenylmethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371112-03-7 HCAPLUS

CN Benzenepropanoic acid, .alpha.-[[[(2S)-cyclohexyl][(1,1-dimethylethoxy)carbonyl]amino]acetyl]oxy]-3-hydroxy-, phenylmethyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371112-04-8 HCAPLUS

CN Benzenepropanoic acid, .alpha.-[[[(2S)-aminocyclohexylacetyl]oxy]-3-hydroxy-, phenylmethyl ester, hydrochloride, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 371112-05-9 HCAPLUS

CN 2,10-Dioxo-13-azatricyclo[15.2.2.13,7]docosa-3,5,7(22),17,19,20-hexaene-9-carboxylic acid, 12-cyclohexyl-11,14-dioxo-, phenylmethyl ester, (9S,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371112-07-1 HCAPLUS

CN 2,10-Dioxa-13-azatricyclo[15.2.2.13,7]docosa-3,5,7(22),17,19,20-hexaene-9-carboxylic acid, 12-cyclohexyl-11,14-dioxo-, (9S,12S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371112-08-2 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-(.alpha.S)-.alpha.,3-dihydroxybenzenepropanoyl-3-amino-2-hydroxyhexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371112-09-3 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-3-hydroxy-L-phenylalanyl-3-amino-2-hydroxyhexanoylglycyl-N,N-dimethyl-2-phenyl-, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371112-10-6 HCAPLUS


CN Benzenepropanoic acid, .alpha.-[[(2S)-cyclohexyl[(7-hydroxy-1-oxoheptyl)amino]acetyl]oxy]-3-hydroxy-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371112-11-7 HCAPLUS
 CN 2,13-Dioxa-10-azabicyclo[14.3.1]eicosa-1(20),16,18-triene-14-carboxylic
 acid, 11-cyclohexyl-9,12-dioxo-, phenylmethyl ester, (11S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 371112-12-8 HCAPLUS
 CN 2,13-Dioxa-10-azabicyclo[14.3.1]eicosa-1(20),16,18-triene-14-carboxylic
 acid, 11-cyclohexyl-9,12-dioxo-, (11S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371112-13-9 HCAPLUS
 CN 2,10-Dioxa-13-azatricyclo[15.2.2.13,7]docosa-3,5,7(22),17,19,20-hexaene-9-
 carboxylic acid, 12-cyclohexyl-11,14-dioxo-, (9R,12S)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 371112-14-0 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[3-(4-hydroxyphenyl)-1-oxopropyl]glycyl-3-hydroxy-D-phenylalanyl-3-amino-2-hydroxyhexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371112-15-1 HCAPLUS

CN L-Lysine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-N6-[(phenylmethoxy)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371112-16-2 HCAPLUS

CN L-Lysine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-N6-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371112-17-3 HCAPLUS


CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-amino-2-hydroxyhexanoyl-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371112-18-4 HCAPLUS

CN Glycine, N-(3-amino-2-hydroxy-1-oxohexyl)-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 371112-19-5 HCAPLUS

CN Glycine, (2S)-2-cyclohexylglycyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-amino-2-hydroxyhexanoyl-, 2-propenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 371112-20-8 HCAPLUS

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-α-glutamyl-(2S)-2-cyclohexylglycyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-amino-2-hydroxyhexanoyl-, 1-(phenylmethyl) 5-(2-propenyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371112-21-9 HCAPLUS

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-glutamyl-(2S)-2-cyclohexylglycyl-L-lysyl-3-amino-2-hydroxyhexanoyl-, 5-propyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 371112-22-0 HCAPLUS

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-glutamyl-(2S)-2-cyclohexylglycyl-L-lysyl-3-amino-2-hydroxyhexanoyl-, 5-propyl ester, (1.fwdarw.3)-lactam (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371112-23-1 HCAPLUS

CN Glycine, N-(3-amino-2-hydroxy-1-oxohexyl)glycyl-2-phenyl-, phenylmethyl ester, monohydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 371112-24-2 HCAPLUS

CN L-Phenylalanine, (2S)-2-cyclohexylglycyl-3-iodo-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 371241-12-2 HCAPLUS

CN Ruthenium(1+), (.eta.5-2,4-cyclopentadien-1-yl)[methyl (2S)-N-[3-(.eta.6-4-chlorophenyl)-1-oxopropyl]-2-cyclohexylglycyl-3-hydroxy-L-phenylalaninate]-, hexafluorophosphate(1-) (9CI) (CA INDEX NAME)


CM 1

CRN 371241-11-1
CMF C32 H38 Cl N2 O5 Ru
CCI CCS


PAGE 1-A



PAGE 1-B



PAGE 2-A




CM 2

CRN 16919-18-9

CMF F6 P

CCI CCS



RN 371241-14-4 HCAPLUS

CN Ruthenium, [(1,2,3,4,5,6-eta.)-4-chlorobenzenebutanoato] (.eta.5-2,4-cyclopentadien-1-yl)-, compd. with hydrogen hexafluorophosphate(1-) (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 371241-13-3


CMF C15 H15 Cl O2 Ru

CCI CCS

PAGE 1-A



PAGE 2-A




CM 2

CRN 16940-81-1

CMF F6 P . H

CCI CCS

● H⁺

RN 371241-18-8 HCAPLUS

CN Ruthenium(1+), (.eta.5-2,4-cyclopentadien-1-yl) [methyl
 (2S)-N-[4-(.eta.6-4-chlorophenyl)-1-oxobutyl]-2-cyclohexylglycyl-3-hydroxy-
 L-phenylalaninate]-, hexafluorophosphate(1-) (9CI) (CA INDEX NAME)


CM 1

CRN 371241-17-7


CMF C33 H40 Cl N2 O5 Ru

CCI CCS


PAGE 1-A



PAGE 1-B




PAGE 2-A



CM 2

CRN 16919-18-9
CMF F6 P

CCI CCS




RN 371241-24-6 HCAPLUS
 CN Ruthenium(1+), (.eta.5-2,4-cyclopentadien-1-yl)[methyl
 (2S)-N-[5-(.eta.6-4-chlorophenyl)-1-oxopentyl]-2-cyclohexylglycyl-3-
 hydroxy-L-phenylalaninate]-, hexafluorophosphate(1-) (9CI) (CA INDEX
 NAME)


CM 1

CRN 371241-23-5
 CMF C34 H42 Cl N2 O5 Ru
 CCI CCS


PAGE 1-A



PAGE 1-B



PAGE 2-A




CM 2

CRN 16919-18-9

CMF F6 P

CCI CCS



RN 371241-28-0 HCAPLUS

CN Ruthenium(1+), (.eta.5-2,4-cyclopentadien-1-yl)[methyl
N-[3-(.eta.6-4-chlorophenyl)-1-oxopropyl]glycyl-3-hydroxy-L-
phenylalaninate]-, hexafluorophosphate(1-) (9CI) (CA INDEX NAME)


CM 1

CRN 371241-27-9


CMF C26 H28 Cl N2 O5 Ru

CCI CCS


PAGE 1-A



PAGE 1-B




PAGE 2-A



CM 2

CRN 16919-18-9
CMF F6 P

CCI CCS




RN 371241-36-0 HCAPLUS
 CN Ruthenium(1+), (.eta.5-2,4-cyclopentadien-1-yl) [methyl
 (2S)-(1,2,3,4,5,6-.eta.)-4-chloro-N-[(1,1-dimethylethoxy)carbonyl]-L-
 phenylalanyl-2-cyclohexylglycyl-3-hydroxy-L-phenylalaninate]-,
 hexafluorophosphate(1-) (9CI) (CA INDEX NAME)


CM 1

CRN 371241-35-9
 CMF C37 H47 Cl N3 O7 Ru
 CCI CCS


PAGE 1-A



PAGE 1-B



PAGE 2-A




CM 2

CRN 16919-18-9

CMF F6 P

CCI CCS



RN 371241-43-9 HCAPLUS

CN Ruthenium(1+), (.eta.5-2,4-cyclopentadien-1-yl) [methyl
(2S)-(1,2,3,4,5,6-.eta.)-N-acetyl-4-chloro-L-phenylalanyl-2-
cyclohexylglycyl-3-hydroxy-L-phenylalaninate]-, hexafluorophosphate(1-)
(9CI) (CA INDEX NAME)


CM 1

CRN 371241-42-8


CMF C34 H41 Cl N3 O6 Ru

CCI CCS


PAGE 1-A



PAGE 1-B



PAGE 2-A




CM 2

CRN 16919-18-9
CMF F6 P


The diagram shows a central phosphorus atom (P) with a '5+' charge. It is bonded to five fluorine atoms (F). Two bonds are solid lines, and three are dashed lines. Each fluorine atom has a negative charge (F⁻).

CM 1



PAGE 1-A



PAGE 1-B



PAGE 2-A




CM 2

CRN 16919-18-9

CMF F6 P

CCI CCS




RN 371241-50-8 HCAPLUS

CN Ruthenium(1+), (.eta.5-2,4-cyclopentadien-1-yl)[(1,17,18,19,20,21-.eta.)-phenylmethyl (9S,12S)-12-cyclohexyl-11,14-dioxo-2,10-dioxa-13-azatricyclo[15.2.2.13,7]docosa-3,5,7(22),17,19,20-hexaene-9-carboxylate]-, hexafluorophosphate(1-) (9CI) (CA INDEX NAME)


CM 1

CRN 371241-49-5
 CMF C38 H40 N O6 Ru
 CCI CCS


PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 2-B



PAGE 3-A




PAGE 3-B

CM 2

CRN 16919-18-9

CMF F6 P

CCI CCS



RN 371241-54-2 HCAPLUS

CN Ruthenium(1+), (.eta.5-2,4-cyclopentadien-1-yl){(1,19,20,21,22,23-.eta.)-methyl (9S,12S)-12-cyclohexyl-11,14-dioxo-2-oxa-10,13-diazatricyclo[17.2.2.13,7]tetracos-3,5,7(24),19,21,22-hexaene-9-carboxylate]-, hexafluorophosphate(1-) (9CI) (CA INDEX NAME)


CM 1

CRN 371241-53-1

CMF C34 H41 N2 O5 Ru

CCI CCS


PAGE 1-A




* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


PAGE 2-A




PAGE 2-B



PAGE 2-C



PAGE 3-A




CM 2

CRN 16919-18-9

CMF F6 P


CCI CCS



RN 371755-64-5 HCAPLUS

CN Glycine, (2S)-2-cyclohexylglycyl-1-(7-carboxyheptyl)-L-histidyl-3-amino-2-hydroxyhexanoylglycyl-2-phenyl-, 5-(1,1-dimethylethyl) ester, (2.fwdarw.1)-lactam, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371755-65-6 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-(7-hydroxy-1-oxoheptyl)glycyl-.alpha.,3-dihydroxybenzenepropanoyl-3-amino-2-hydroxyhexanoyl-glycyl-N,N-dimethyl-2-phenyl-, cyclic (1.fwdarw.2)-ether, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 371112-06-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of macrocyclic NS3-serine protease inhibitors of
hepatitis C virus)

RN 371112-06-0 HCAPLUS

CN 2,10-Dioxa-13-azatricyclo[15.2.2.13,7]docosa-3,5,7(22),17,19,20-hexaene-9-carboxylic acid, 12-cyclohexyl-11,14-dioxo-, phenylmethyl ester, (9R,12S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> log hold
COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE
ENTRY 9.05

TOTAL
SESSION 554.35

SINCE FILE
ENTRY -0.65

TOTAL
SESSION -6.51

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:09:35 ON 07 MAY 2003

554
- 509

45